Breast Cancer

ASCO/CAP Clinical Practice Guideline Focused Update on HER2 Testing in Breast Cancer

As reported in the Journal of Clinical Oncology by Antonio C. Wolff, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and colleagues...

 

Multiple Myeloma

Once- vs Twice-Weekly Carfilzomib in Relapsed or Refractory Multiple Myeloma

An interim analysis of the phase III ARROW trial reported in The Lancet Oncology by Moreau et al indicated that a higher-dose once-weekly schedule...

 

Lung Cancer

Final Overall Survival Analysis of First-Line Crizotinib vs Chemotherapy in Advanced ALK-Positive NSCLC

As reported by Solomon and colleagues in the Journal of Clinical Oncology, the final overall survival results of the phase III PROFILE 1014 trial...

 


Advertisement
Issues in Oncology

Informed Consent Issues for Patients With Advanced Cancer in Phase I Trials

As reported by Hlubocky et al in the Journal of Oncology Practice, oncologists may not provide patients with advanced cancer participating in phase I clinical trials...

 

Breast Cancer

Low-Fat Dietary Intervention and Overall Survival After Breast Cancer Diagnosis

In an analysis from the Women’s Health Initiative (WHI) trial reported in JAMA Oncology, Chlebowski et al found that overall survival after the diagnosis of incident breast cancer...

 


More Top Stories

Lung Cancer

Gilberto Lopes, MD, MBA, on NSCLC: Results From the KEYNOTE-042 Trial

Hematologic Malignancies
Lymphoma

Hematopoietic Cell Transplantation for Follicular Lymphoma

Many patients with follicular lymphoma relapse within 2 years of initial therapy, and for a number of these individuals, hematopoietic cell transplantation is a good treatment option. Transplant, however, both autologous and allogeneic, is vastly underutilized in these patients, according to...

Advertisement

Suboptimal Use of Initial Chemotherapy in Newly Diagnosed AML

In a study of National Cancer Database data reported in Blood Advances, Bhatt et al found that 25% of patients with newly diagnosed acute myeloid leukemia (AML) did not receive initial chemotherapy, despite evidence that chemotherapy is associated with a survival benefit and improvement in symptoms ...

Kidney Cancer

Toni K. Choueiri, MD, and Lauren C. Harshman, MD on RCC: Results From the PROSPER Trial

Solid Tumors

Phase I Study of ERK1/2 Inhibitor in Advanced Solid Tumors

Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in BRAF- and RAS-mutant cell lines. Now, a multicenter phase I study investigating its safety and efficacy in the treatment of patients with advanced solid tumors has found that ulixertinib has an acceptable...

AACR and Cancer Research UK Form Alliance

The American Association for Cancer Research (AACR) in collaboration with Cancer Research UK (CRUK) are launching a new international alliance to stimulate discoveries in cancer research. The two organizations share the vision that significant progress against cancer could be facilitated by...

DNA Test Identifies Men With Sixfold Increased Risk of Prostate Cancer

A major new study of more than 140,000 men has identified 63 new genetic variations in the DNA code that increase the risk of prostate cancer. These findings were published by Schumacher et al in Nature Genetics. Researchers devised a new test combining these single-letter genetic variants with...

Issues in Oncology

Lee S. Schwartzberg, MD, on Using Immunotherapy in the Community Setting: 2018 Update on an ACCC Program

Spotlight on Women Who Conquer Cancer

WOMEN WHO CONQUER CANCER is a group dedicated to advancing cancer research by supporting young women researchers early in their careers through Conquer Cancer Foundation of ASCO Young Investigator Awards (YIAs). These 1-year grants give promising researchers the boost they need to get started on...

Advertisement

Parents See Cancer Prevention Potential as Best Reason for HPV Vaccination

Parents of adolescents believed that the potential to prevent certain types of cancer is the best reason for their children to receive the human papillomavirus (HPV) vaccine, whereas other reasons health-care providers often give were far less persuasive. Findings from this study were published by...


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.